Niagen Bioscience, Inc. (NAGE) · Nov 4, 2026 · Earnings

Niagen Bioscience earnings miss as 2026 e-commerce outlook resets lower

Miss — Revenue $27.2M vs ~$34.45M consensus; EPS -$0.01 vs ~$0.02 consensus

Niagen Bioscience earnings missed on revenue and EPS, with weaker e-commerce forcing a lower 2026 outlook despite new product launches.

Niagen Bioscience is trying to use its consumer supplement business to fund a broader NAD+ platform spanning injectables, skincare, and pharmaceutical development. Management had already framed 2026 as an investment year, but the prior outlook still called for 10%–15% e-commerce growth; the new release lowers that expectation to approximately 5%.

The quarter was a clear earnings miss, not just a noisy transition quarter. Revenue fell 20% year over year to $27.2 million, versus published expectations of roughly $34.45 million, while EPS was a $0.01 loss versus an expected roughly $0.02 profit. The shortfall is large enough to show that near-term commercial weakness is overpowering the company’s growth investments.

The core consumer engine is losing momentum faster than the launch narrative suggests. Direct-to-consumer sales grew 13% year over year, below the previously stated 15%–20% full-year direct-website target, while the broader e-commerce outlook was reduced from 10%–15% growth to approximately 5%. Management itself described the quarter as involving “near-term commercial headwinds.” 〔0〕

The outlook change is the most important forward-looking negative. The company now expects the rest of its consumer business to offset only approximately 5% e-commerce growth, while the ingredient business is expected to decline because of competitive pressure at key partners. That means the new skincare, Niagen Plus, and pharmaceutical initiatives are not yet replacing the lost momentum; management says the first two are not expected to become meaningful contributors until 2027. 〔1〕 〔2〕

The balance sheet gives the company time, but not proof of the strategy. Cash reached $69.5 million with no borrowings, and operations remained cash-positive, allowing continued spending on brand-building, distribution, skincare, and NB4168. But adjusted EBITDA collapsed from $6.4 million to $0.5 million, so the company is funding expansion from a much weaker operating base than last year.

The new launches are strategically useful but economically too early to offset the miss. NanoCloud skincare, the ready-to-inject Niagen Plus product, distribution, and the NB4168 development effort broaden the platform, but this filing provides no material revenue contribution from those initiatives yet. The business story remains intact as a longer-term platform build, but the near-term execution bar has moved lower.

Bottom line: Niagen is still building the broader NAD+ platform, but Q3 shows the funding engine weakening sharply before the new businesses scale. The lower e-commerce outlook makes this a meaningful negative reset, even with ample cash and continued strategic progress.

What to watch next

Q4 2026 results and first 2027 contribution from skincare and Niagen Plus

Original filing on SEC EDGAR